Replies to post #294014 on Avid Bioservices Inc (CDMO)

[biopharm]

Janne Pasi

Looks like Janne Pasi working with AstraZeneca and we shall see where these puzzle pieces lead....

"...Combination Chemotherapy

Most recently, Dr. Janne and collaborators at 67 medical centers and clinics in 12 countries have reported some success with a compound of the standard chemotherapy agent Docetaxel in combination with Selumetinib, a drug manufactured by AstraZeneca. The drugs are combined for the treatment of advanced-stage non-small cell lung cancer in patients whose tumors carry a mutation in the gene KRAS. These tumors account for about 20 percent of NSCLC cases, but, so far, no targeted therapy has proved effective against them.

According to Dr. Janne, the clinical trial demonstrated that “a combination of chemotherapy and Selumetinib is significantly better than chemotherapy alone for this group of patients – better in terms of tumor response to therapy and in terms of survival times prior to advance of the disease. It suggests that for the first time we may have an effective treatment for KRAS-mutant lung cancer, which is the largest single subtype of the disease.”
..
...
https://www.asbestos.com/treatment/doctors/pasi-a-janne.php

----

Hmmmm....who knows where these pieces lead, especially when Merck is in the race to ....and Jimmy Carter ....hmmm

""I suspect the findings were significant enough that this will be a practice-changing finding," Dr. Pasi Janne, lung cancer specialist at Harvard Medical School and the Dana-Farber Cancer Institute, told NBC News."

https://www.google.com/amp/www.nbcnews.com/health/cancer/amp/lung-cancer-trial-stopped-after-jimmy-carter-drug-stops-tumors-n593726

[biopharm]

..propietary CSF1R inhibitor program"

Now I say Peregrine was involved with CSF1R inhibitor program and was nondisclosed ...

....Eli Lilly digging deeper into CSF1R and Peregrine must unveil a bit of their non disclosed collaborations


Colony-stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), is a cell-surface receptor for its ligands, colony-stimulating factor 1 (CSF1) and IL-34.1,2 CSF1R plays an important role as regulator of the development, morphology, survival, and functions of tissue macrophages as well as tumor-associated macrophages (TAMs). CSF1 is involved in the recruitment and survival of macrophages in tumors. Increased CSF1 expression is implicated in tumor progression and metastasis, and is associated with poor prognosis in some cancers.3
Molecule

LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R, preventing ligands CSF1 and IL-342 from binding to the receptor and inhibiting TAMs from receiving CSF1 signals, decreasing their survival and relieving the effect of TAMs in the tumor.4

Clinical Development

LY3022855 (IMC-CS4) is being investigated in phase I clinical trials, including a collaboration clinical trial with another immuno-oncology agent.

http://www.lillyoncologypipeline.com/molecule/csf-1-r-antibody/overview

[biopharm]

though Janne Pasi goes back to moderator for David Gerber back in Sept 2012

Where is Astra Zeneca? I am surprised to have not heard from Helen Angell regarding Immunoscore Biomarkers and Helen works with Jerome "Jerry" Galon re: Immunoscore so Helen at AstraZeneca makes sense but know to see Jani Passe in the mix would make it like a global effort in this biomarkers new age to predict disease and stage it

http://www.jto.org/article/S1556-0864(17)30608-1/pdf